Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.

Herstein JE; Marx KR; Haddad FG; Chien KS; Hammond D; Short NJ; Kadia TM; Daver NG; Ravandi F; Garcia-Manero G; DiNardo CD

doi:10.1080/10428194.2026.2621831

← 뒤로

Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.

Leukemia & lymphoma 2026 p. 1-3

Herstein JE, Marx KR, Haddad FG, Chien KS, Hammond D, Short NJ, Kadia TM, Daver NG, Ravandi F, Garcia-Manero G, DiNardo CD

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Herstein JE, Marx KR, et al. (2026). Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.. Leukemia & lymphoma, 1-3. https://doi.org/10.1080/10428194.2026.2621831

MLA Herstein JE, et al.. "Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.." Leukemia & lymphoma, 2026, pp. 1-3.

PMID 41623269

DOI 10.1080/10428194.2026.2621831

같은 제1저자의 인용 많은 논문 (1)

Case Report: FIA plus venetoclax in a patient on hemodialysis.
Frontiers in oncology 2025